TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 juil. 2022 16h15 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer
27 juin 2022 06h45 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 juin 2022 16h21 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR² Therapeutics to Participate in Two Upcoming Conferences in June
01 juin 2022 06h45 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
12 mai 2022 06h45 HE
|
TCR2 Therapeutics
- Initiated Phase 2 expansion portion of the ongoing gavo-cel clinical trial- IND Clearance for Phase 1/2 clinical trial of TC-510- 30 patients treated with gavo-cel in the expanded Phase 1 trial;...
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 mai 2022 17h32 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 avr. 2022 16h15 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
TCR² Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update
22 mars 2022 06h45 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients...
TCR² Therapeutics to Highlight Off-the-Shelf TRuC-T Cell at the American Association of Cancer Research Annual Meeting 2022
08 mars 2022 16h30 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 mars 2022 16h15 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...